Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00966446
Other study ID # 809899
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2009
Est. completion date December 2014

Study information

Verified date July 2019
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall goal of this project is to elucidate the epidemiology of MRSA transmission in the community and test an intervention to prevent MRSA transmission in this setting.


Description:

The overall goals of this project are to:

1. to investigate the determinants of and evaluate potential interventions to reduce the spread of methicillin resistant Staphylococcus aureus (MRSA) infections in community settings in order to reduce the burden of this illness in the State of Pennsylvania. This objective has the following specific aims:

- to identify host, microbiological and environmental risk factors for prolonged MRSA colonization, MRSA transmission and clinical MRSA infection among patients with MRSA skin and soft tissue infections (SSTIs) and their household contacts and to use stochastic agent-based modeling methods to quantify secondary spread of CO-MRSA in households.

- to evaluate the impact of a decolonization intervention on MRSA infections in the household.

- to identify immunological mechanisms underlying the ability of Streptococcus pneumoniae colonization to inhibit MRSA colonization, transmission and infection in order to identify potential future immunological targets for interventions.

2. to foster multi-disciplinary and cross-institutional collaborations and develop the infrastructure for a Center of Excellence focused on antimicrobial drug resistance research, with the capacity for activities linking basic science, epidemiological and clinical intervention studies

3. to enhance opportunities for basic and clinical research training for undergraduate and graduate students, particularly from underrepresented minorities, in order to increase the pipeline of future biomedical scientists and clinical investigators


Recruitment information / eligibility

Status Completed
Enrollment 223
Est. completion date December 2014
Est. primary completion date September 2014
Accepts healthy volunteers No
Gender All
Age group 6 Months and older
Eligibility Inclusion Criteria:

- All members of a household in which the index case is treated for a skin or soft tissue infection due to MRSA. All household members must agree to participate in order for the household to be enrolled

Exclusion Criteria:

- Prior MRSA within past 6 months in the index case; age less than 6 months.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Unsupervised Decolonization
Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.
Supervised Decolonization
Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure compliance, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.

Locations

Country Name City State
United States Hershey Medical Center Hershey Pennsylvania
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States Penn Presbyterian Medical Center Philadelphia Pennsylvania

Sponsors (4)

Lead Sponsor Collaborator
University of Pennsylvania Children's Hospital of Philadelphia, Milton S. Hershey Medical Center, Pennsylvania Department of Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrent Infection Confirmed new MRSA infections Within 6 months
Primary First Two Consecutive Sampling Periods Completed Subjects who returned samples for at least the first two consecutive sampling periods were included in analysis Within 2 months
Secondary Time to Clearance of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization Surveillance cultures negative for two consecutive sampling periods; date of clearance determined as midpoint between date of last positive surveillance culture and first negative surveillance culture. Within 6 months
See also
  Status Clinical Trial Phase
Completed NCT01786161 - Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients Phase 4
Active, not recruiting NCT02572791 - Staph Household Intervention for Eradication (SHINE) Phase 4
Recruiting NCT01612052 - Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2) Phase 4
Terminated NCT01400308 - Effectiveness of Two Protocols for Corporal Decolonization in Patients Colonized by Methicillin Resistant Staphylococcus Aureus (MRSA) Phase 4